Zydus receives Post Application Action Letter for the USFDA cGMP nd Pre-Approval Inspection at the Ahmedabad API facility

Zydus Lifesciences Ltd has received Post Application Action Letter from the USFDA for the inspection conducted at the Ahmedabad API facility, confirming that the inspected facility has been considered as ready to commercially manufacture and supply the API. This facility underwent for-cause cGMP surveillance and Pre-Approval Inspection for manufacturing of drug substances Enzylutamide from 14th to 22nd Dec 2023.

Shares of Zydus Lifesciences Limited was last trading in BSE at Rs. 976.80 as compared to the previous close of Rs. 962.05. The total number of shares traded during the day was 102005 in over 3281 trades.

The stock hit an intraday high of Rs. 982.10 and intraday low of 958.55. The net turnover during the day was Rs. 98773258.00.

Source : Equity Bulls

Keywords

ZydusLifesciences INE010B01027 PostApplicationActionLetter USFDA Ahmedabad APIFacility